Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of $(0.13) per share
Aclaris lost less money than people expected this quarter, which is good news for a company still growing. When a company does better than expected, it can mean their business is getting stronger, so that's worth watching.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.